{
  "$schema": "folio-library-entry/v1",
  "id": "10665-352522",
  "blocks": [
    {
      "id": "library/10665-352522/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 7,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "WHO \n consolidated \nguidelines on \ntuberculosis\nModule 5: Management \nof tuberculosis in children \nand adolescents\nWHO \n\u0003consolidated \nguidelines on\u0003 \ntuberculosis\nModule 5: Management \nof tuberculosis in children \nand adolescents\nWHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents \nISBN 978–92–4-004676–4 (electronic version)\nISBN 978–92–4-004677–1 (print version)\n© World Health Organization 2022\nSome rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence \n(CC BY-NC-SA 3.0",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of the WHO consolidated tuberculosis guidelines, Module 5 on managing tuberculosis in children and adolescents (2022), with ISBNs, licence terms, contents and links to web annexes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 7,
      "pageEnd": 11,
      "target": "../sections/sec-000-acknowledgements.md",
      "narrative": null,
      "content": "Acknowledgements \nThe production and writing of the WHO consolidated guidelines on tuberculosis. Module 5: management \nof tuberculosis in children and adolescents, 2022 was coordinated by Sabine Verkuijl, Annemieke Brands, \nKerri Viney and Tiziana Masini, under the guidance of Farai Mavhunga, head of the TB Vulnerable \nPopulations, Communities and Comorbidities unit and the overall direction of Tereza Kasaeva, Director \nof the World Health Organization (WHO) Global Tuberculosis (TB) Programme. Colleagues from the \nPrevention, Diagnosis, Treatment, Care and Innovation Unit, Global TB Programme,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges those who coordinated and contributed to the 2022 guidelines on tuberculosis in children and adolescents, led by the WHO Global Tuberculosis Programme. It lists the Guideline Development Group members with their institutions, along with reviewers, observers and the systematic review teams. Funding for the update came from Unitaid and USAID.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Abbreviations",
      "pageStart": 11,
      "pageEnd": 13,
      "target": "../sections/sec-001-abbreviations.md",
      "narrative": null,
      "content": "Abbreviations \nAIDS\t\nacquired immunodeficiency syndrome\nANC\t\nantenatal care\nART\t\nantiretroviral treatment\nBCG\t\nbacille Calmette-Guérin\nC(A)LHIV\t\nchildren (and adolescents) living with HIV infection\nCHW\t\ncommunity health worker\nCXR\t\nchest X-ray or chest radiography\nDR-TB\t\ndrug-resistant tuberculosis \nDS-TB\t\ndrug-susceptible tuberculosis\nDST\t\ndrug susceptibility testing\nDTG\t\ndolutegravir\nE\t\nethambutol\nEPTB\t\nextrapulmonary TB\nEto\t\nethionamide\nFDC\t\nfixed-dose combination (medicines)\nGDF\t\nStop TB Partnership Global Drug Facility\nGDG\t\nGuideline Development Group\nGRADE\t\nGrading of Recommendations Ass",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The list of abbreviations used in the guidelines on tuberculosis in children and adolescents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Definitions",
      "pageStart": 13,
      "pageEnd": 19,
      "target": "../sections/sec-002-definitions.md",
      "narrative": null,
      "content": "Unless otherwise specified, the terms defined here apply as used in this document. They may have \ndifferent meanings in other contexts.\nActive (tuberculosis) case-finding: Provider-initiated screening and testing in communities by \nmobile teams, often using mobile X-ray and rapid molecular tests. The term is sometimes used \nsynonymously with “systematic screening”.\nAdherence: Extent to which a person’s behaviour (e.g. taking medicines, following a particular diet, \nchanging lifestyle) corresponds with agreed recommendations from a health care provider.\nAdvanced HIV disease: For adolescents and",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines terms used in the guidelines, such as active case-finding, adherence, advanced HIV disease, adverse events and age groups from infant to adolescent. Many further definitions cover diagnostic, treatment, drug-resistance and outcome terms. Definitions apply to this document and may differ elsewhere. The section ends with references, including WHO consultations on outcome definitions.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Executive summary",
      "pageStart": 19,
      "pageEnd": 25,
      "target": "../sections/sec-003-executive-summary.md",
      "narrative": null,
      "content": "Introduction \nChildren and young adolescents (aged below 15 years) represent about 11% of all people with \ntuberculosis (TB) globally. This means that 1.1 million children become ill with TB every year, almost \nhalf of them below five years of age. National TB programmes (NTPs) only notify less than half of \nthese children, meaning that there is a large case detection gap (1). The reasons for this gap include \nchallenges with specimen collection and bacteriological confirmation of TB in young children, due \nto the paucibacillary nature of TB disease in this age group and the lack of highly sen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises the 2022 guidelines, noting that about 1.1 million children fall ill with tuberculosis each year and fewer than half are notified, with low uptake of preventive treatment among young contacts. It sets out global targets, the rationale for updating the 2014 guidance, the objectives and the target audience. It lists the eight new recommendations, including Xpert Ultra as the first test on several specimen types, treatment decision algorithms, a 4-month regimen for non-severe tuberculosis, bedaquiline and delamanid for young children with drug-resistant tuberculosis and a 6-month regimen for tuberculous meningitis. A table of consolidated existing recommendations follows, covering areas such as HIV care, nutrition and contact investigation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1: New recommendations in the WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents, 2022",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table lists the eight new or updated recommendations on the management of TB in children and adolescents from the 2022 WHO consolidated guidelines, grouped under diagnostic approaches, treatment regimens and models of TB care. Each recommendation is followed by its status (new or updated), strength and certainty of evidence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352522/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2: Recommendations in the WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents, 2022, by chapter and topic",
      "pageStart": 21,
      "pageEnd": 23,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "The table lists the topics covered by recommendations in the 2022 WHO consolidated guidelines on the management of TB in children and adolescents, by chapter: screening and contact investigation, prevention, diagnostic approaches, treatment, models of TB care and special situations.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 25,
      "pageEnd": 25,
      "target": "../sections/sec-004-1-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Background",
      "pageStart": 25,
      "pageEnd": 26,
      "target": "../sections/sec-005-11-background.md",
      "narrative": null,
      "content": "Children and young adolescents (aged below 15 years) represent about 11% of all people with TB \nglobally. This means that close to 1.1 million children become ill with TB every year, almost half of them \nbelow five years of age. National TB programmes (NTPs) only notify less than half of these children, \nmeaning that there is a large case detection gap (1). The reasons for this gap include challenges with \nspecimen collection and bacteriological confirmation of TB in young children, due to the paucibacillary \nnature of TB disease in this age group and the lack of highly sensitive point-of-care",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the background to the guidelines, noting the burden of tuberculosis in children and young adolescents, the case detection gap due to diagnostic difficulties and the 24% fall in child notifications in 2020 linked to COVID-19. It also mentions low preventive treatment coverage and explains that this update brings all relevant recommendations together in one guideline.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Rationale for the development of the 2022 consolidated guidelines",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-006-12-rationale-for-the-development-of-the-2022-con.md",
      "narrative": null,
      "content": "consolidated guidelines \nSince the publication of the WHO Guidance for national tuberculosis programmes on the \nmanagement of tuberculosis in children (second edition) (2014) (8), there have been numerous studies, \nincluding reviews, randomized controlled trials, observational studies, pharmacokinetic (PK) and \npharmacodynamic studies, qualitative research and cost-effectiveness research, which have evaluated \nthe impact of various interventions. These are related to diagnostic approaches for TB, treatment for \ndrug-susceptible TB (DS-TB), drug-resistant TB (DR-TB) and TB meningitis (TBM), as",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that new research since the 2014 WHO guidance on childhood tuberculosis prompted a review and update, with new and existing recommendations brought together in one consolidated guideline.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Objectives of the 2022 consolidated guidelines",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-007-13-objectives-of-the-2022-consolidated-guideline.md",
      "narrative": null,
      "content": "The objectives of the 2022 consolidated guidelines on the management of TB in children and \nadolescents are to:\n1.\t provide policy-makers and implementing partners with evidence-based recommendations on the \nentire cascade of care for children and adolescents to support the implementation of activities \nto prevent TB among children and adolescents at risk, and to improve TB case detection and \ntreatment outcomes in children and adolescents with TB, using effective models of care; and \n2.\t contribute to reductions in TB-related morbidity and mortality in children and adolescents in \nline with g",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States the guidelines' objectives: to give evidence-based recommendations across the cascade of care for children and adolescents and to help cut tuberculosis illness and death in line with global targets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Target audience",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../sections/sec-008-14-target-audience.md",
      "narrative": null,
      "content": "The target audience for these consolidated guidelines consists primarily of NTPs, primary health \ncare (PHC) programmes, maternal and child health programmes, national AIDS programmes (or \ntheir equivalents in health ministries) and other health policy-makers. They also target generalist \nand specialist paediatricians, clinicians and health practitioners working on TB, HIV and/or infectious \ndiseases in public and private sectors, the educational sector, nongovernmental, civil society and \ncommunity-based organizations, as well as technical and implementing partners.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies the target audience as tuberculosis, primary care, maternal and child health and AIDS programmes, clinicians, and civil society and implementing partners.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "WHO recommendations relevant to the management of TB in children and adolescents",
      "pageStart": 26,
      "pageEnd": 27,
      "target": "../sections/sec-009-15-who-recommendations-relevant-to-the-managemen.md",
      "narrative": null,
      "content": "management of TB in children and adolescents\nThe 2022 consolidated guidelines represent a significant update compared to the previous guidelines \nissued in 2014. They include: (i) new recommendations based on the review of newly available \nevidence related to the Population, Intervention, Comparator and Outcomes (PICO) questions that \nwere developed for this guideline update; (ii) recommendations with relevance to children and \nadolescents from other WHO TB guidelines issued since 2014; and (iii) a few recommendations from \nthe 2014 guidance that remain unchanged. These latter recommendations",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the 2022 WHO consolidated guidelines on managing TB in children and adolescents combine new evidence-based recommendations, relevant recommendations from other WHO TB guidelines since 2014 and some unchanged 2014 recommendations. It notes that source wording and age definitions are kept and points users to the WHO TB Knowledge Sharing Platform and web annexes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Scope of the guideline update",
      "pageStart": 27,
      "pageEnd": 30,
      "target": "../sections/sec-010-16-scope-of-the-guideline-update.md",
      "narrative": null,
      "content": "The population of interest in these guidelines is children and adolescents, defined as:\n•\t A child is a person under 10 years of age.\n•\t An adolescent is a person 10–19 years of age (inclusive).\nThe pathway of TB infection and disease in an individual child or adolescent, and the interface with \nand retention across sequential stages of care (termed the ‘cascade of care’) was used as the analytic \nframework during the scoping process for this guideline update (Figure 1) (10). This pathway involves \nmultiple steps from exposure to a person with an infectious form of TB, leading to subsequent TB",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets the scope of the guideline update, defining children as under 10 and adolescents as 10–19 years, and uses the cascade of care from TB exposure to treatment outcome as its analytical framework, shown in a figure. It lists the PICO questions addressed, on diagnosis, treatment and models of care such as decentralized and family-centred integrated services. Two background questions concern the socioeconomic impact of TB on families and how best to engage adolescents in care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/figure-vfig-p028",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 28,
      "pageEnd": 28,
      "target": "../figures/vfig-p028.webp",
      "narrative": "draft",
      "content": "Page render showing the lower part of Figure 1, a cascade of TB care in children and adolescents drawn as branching paths from susceptible to exposed to infected, then to preventive treatment, diseased, did not access the health care system, or un/misdiagnosed, with PICO labels for screening in health care facilities and models of care. Below it, Figure 2 is a logic model of four linked boxes: inputs (e.g. stakeholder engagement, financial and human resources, evidence from research), activities (e.g. contact investigation, TB screening, diagnostic approaches, treatment regimens, models of care), short-term outcomes (e.g. earlier detection of DS- and DR-TB, improved treatment outcomes, increased preventive treatment coverage) and long-term outcomes (reduced TB incidence, mortality, post-TB sequelae and financial losses).",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Publication, dissemination, evaluation and expiry",
      "pageStart": 30,
      "pageEnd": 30,
      "target": "../sections/sec-011-17-publication-dissemination-evaluation-and-expi.md",
      "narrative": null,
      "content": "The electronic version of the consolidated guidelines on the management of TB in children and \nadolescents will form part of the WHO TB KSP, which features the following components for each TB \nmodule: (i) consolidated guidelines, (ii) operational handbooks with implementation guidance; as well \nas (iii) a catalogue of WHO e-learning materials.\nFurther dissemination strategies include global, regional and country webinars and consultations, \ndevelopment of training materials based on the guideline and the operational handbook, and technical \nsupport for countries during programme reviews and o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes how the guidelines will be published on the WHO TB Knowledge Sharing Platform and disseminated through webinars, training and technical support, and lists the age-disaggregated indicators that will be monitored. It states that the recommendations will be reviewed within five years, and the interim recommendation on treatment decision algorithms within two years.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Document structure",
      "pageStart": 30,
      "pageEnd": 33,
      "target": "../sections/sec-012-18-document-structure.md",
      "narrative": null,
      "content": "A summary of the structure of the guidelines including a brief description of the contents is provided \nin Box 1. \n\t\nÎ Chapter 1 is the introduction and provides background information, an overview of the \nscope (including PICO and background questions), the rationale, objectives and target \naudience for the guidelines.\n\t\nÎ Chapter 2 includes WHO recommendations on TB screening and contact investigation \nthat are relevant to children and adolescents. While no new recommendations were made \nin these areas by the GDG on the management of TB in children and adolescents, new \nrecommendations on TB",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Outlines the structure of the 2022 guidelines chapter by chapter, from the introduction through screening and contact investigation, prevention, diagnosis and treatment to care of children with TB and HIV or malnutrition. It notes which chapters contain new recommendations and that the final chapter sets out research priorities.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "TB screening and contact investigation",
      "pageStart": 33,
      "pageEnd": 35,
      "target": "../sections/sec-013-2-tb-screening-and-contact-investigation.md",
      "narrative": null,
      "content": "2. TB screening and contact \ninvestigation\nThis chapter includes current WHO recommendations that apply to children and adolescents on TB \nscreening and contact investigation. They have been consolidated from current WHO guidelines \non systematic screening for TB disease and contact investigation, namely the WHO consolidated \nguidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease (11) \nand Guidance for national tuberculosis programmes on the management of tuberculosis in children \n(second edition) (8). For more information on each recommendation includi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens chapter 2 by consolidating existing WHO recommendations on TB screening and contact investigation relevant to children and adolescents. Table 3 lists recommendations such as systematically screening household contacts and people living with HIV, and HIV counselling and testing of contacts depending on HIV prevalence.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3: WHO recommendations on TB screening and contact investigation relevant to children and adolescents",
      "pageStart": 33,
      "pageEnd": 34,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "The table compiles current WHO recommendations on TB screening and contact investigation that apply to children and adolescents. Recommendations are grouped by source guideline and topic (screening in targeted populations, tools for screening, HIV counselling and testing of contacts), each with its strength and certainty of evidence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Prevention of TB",
      "pageStart": 35,
      "pageEnd": 41,
      "target": "../sections/sec-014-3-prevention-of-tb.md",
      "narrative": null,
      "content": "This chapter includes current WHO recommendations that apply to children and adolescents on TB \nprevention. They have been consolidated from current WHO guidelines on TB infection, prevention \nand control, a BCG position paper and guidelines on TPT, namely the WHO guidelines on tuberculosis \ninfection prevention and control, 2019 update (12), the BCG vaccines: WHO position paper (published in \nthe Weekly Epidemiological Record) (13) and the WHO consolidated guidelines on tuberculosis. Module 1: \nprevention – tuberculosis preventive treatment (14). For more information on each recommendation \ni",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Consolidates WHO recommendations on TB prevention relevant to children and adolescents, drawn from guidelines on infection prevention and control, the BCG vaccine position paper and guidelines on TB preventive treatment. Table 4 lists measures such as triage and respiratory isolation of people with TB symptoms, BCG vaccination, testing for TB infection and preventive treatment regimens. Recommendations on preventive therapy for people living with HIV, including 36 months of isoniazid in high-transmission settings, close the section.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 4: WHO recommendations on TB infection prevention and control, BCG vaccination and TPT relevant to children and adolescents",
      "pageStart": 35,
      "pageEnd": 39,
      "target": "../tables/table-4.csv",
      "narrative": "draft",
      "content": "The table compiles current WHO recommendations relevant to children and adolescents on TB infection prevention and control (administrative, environmental and respiratory protection controls), BCG vaccination and TB preventive treatment. Recommendations are grouped by source guideline and topic, with their strength and certainty of evidence where given.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Diagnostic approaches for TB in children and adolescents",
      "pageStart": 41,
      "pageEnd": 42,
      "target": "../sections/sec-015-4-diagnostic-approaches-for-tb-in-children-and-a.md",
      "narrative": null,
      "content": "in children and adolescents\nOf the estimated 1.1 million children who developed TB annually, only 399 000 (36.5%) were notified \nto NTPs in 2020. Under-notification is worst among children below 5 years of age, with only 27.5% of \nchildren with TB being notified (1). These ‘missing’ children are not diagnosed and/or not reported. \nTB-related mortality among children below 15 years of age was estimated at 226 000 for 2020 (1). \nModelling has shown that 80% of TB-related deaths are among children under 5 years of age, and \nthat 96% of children who die of TB, did not access treatment (15).\nThe lo",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the gap in TB diagnosis among children, with only about a third of an estimated 1.1 million cases notified in 2020 and most deaths occurring in under-fives who never received treatment. It explains causes such as paucibacillary disease, lack of a sensitive point-of-care test, sampling difficulties and limited primary care capacity, and notes a 2021 expert consultation advising that intrathoracic lymph node TB be classified as pulmonary TB.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "The use of the Xpert MTB/RIF Ultra assay in gastric aspirate and stool specimens for the diagnosis of pulmonary TB and rifampicin resistance",
      "pageStart": 42,
      "pageEnd": 46,
      "target": "../sections/sec-016-41-the-use-of-the-xpert-mtbrif-ultra-assay-in-ga.md",
      "narrative": null,
      "content": "in gastric aspirate and stool specimens for the \ndiagnosis of pulmonary TB and rifampicin resistance\nRecommendation:\nIn children with signs and symptoms of pulmonary TB, Xpert Ultra should be used as the \ninitial diagnostic test for TB and detection of rifampicin resistance on sputum, nasopharyngeal \naspirate, gastric aspirate or stool, rather than smear microscopy/culture and phenotypic drug \nsusceptibility testing (DST). \n(Strong recommendation, moderate certainty of evidence for test accuracy in stool and gastric \naspirate; low certainty of evidence for test accuracy in sputum; very low cer",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends Xpert MTB/RIF Ultra as the initial test for pulmonary TB and rifampicin resistance in children using sputum, nasopharyngeal aspirate, gastric aspirate or stool, instead of smear microscopy, culture and phenotypic drug susceptibility testing. It sets out the justification and evidence, noting the limited sensitivity of the earlier Xpert MTB/RIF assay among children and people with HIV. Implementation considerations cover acceptability and feasibility of specimen collection, and monitoring advice covers laboratory registers and reporting notifications by five-year age group.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment decision algorithms for the diagnosis of pulmonary TB in children aged below 10 years of age",
      "pageStart": 46,
      "pageEnd": 50,
      "target": "../sections/sec-017-42-treatment-decision-algorithms-for-the-diagnos.md",
      "narrative": null,
      "content": "of pulmonary TB in children aged below 10 years \nof age\nInterim recommendation\nIn children with presumptive pulmonary TB attending health care facilities, integrated treatment \ndecision algorithms may be used to diagnose pulmonary TB. \n(Conditional recommendation, very low certainty of evidence).\nRemarks\n•\tPresumptive TB refers to a person who presents with symptoms and/or signs suggestive of \nTB.24\n•\tBacteriological confirmation should be sought as part of the integrated treatment decision \nalgorithms whenever possible, using WHO recommended rapid diagnostic tests and \nappropriate paediatric",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives an interim conditional recommendation that integrated treatment decision algorithms may be used to diagnose pulmonary TB in children under 10 with presumptive TB, while still seeking bacteriological confirmation where possible. It explains that new algorithms are detailed in the operational handbook and that the recommendation will be reviewed after 24 months. The section covers the evidence, the need to suspect drug-resistant TB where relevant, and monitoring of treatment response and outcomes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Consolidated recommendations on TB diagnostics and diagnostic approaches relevant to children and adolescents",
      "pageStart": 50,
      "pageEnd": 55,
      "target": "../sections/sec-018-43-consolidated-recommendations-on-tb-diagnostic.md",
      "narrative": null,
      "content": "diagnostics and diagnostic approaches relevant to \nchildren and adolescents\nTable 5: WHO recommendations on diagnostic approaches relevant to children and \nadolescents\nWHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics \nfor tuberculosis detection, 2021 update (16) \nRecommendations on Xpert MTB/RIF and Xpert Ultra as initial tests in adults and \nchildren with signs and symptoms of pulmonary TB (Note that in these guidelines, adults \nrefer to persons aged 15 years and above and children aged below 15 years, therefore the \nadult population includes older adolesce",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Table 5 consolidates WHO recommendations on TB diagnostics relevant to children and adolescents, including Xpert MTB/RIF and Ultra as initial tests on various specimen types and molecular tests for detecting drug resistance. It notes that adults in the source guidelines include adolescents aged 15 and over, and states that commercial serodiagnostic tests should not be used for children. The page ends with the opening of chapter 5 on treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5: WHO recommendations on diagnostic approaches relevant to children and adolescents",
      "pageStart": 50,
      "pageEnd": 54,
      "target": "../tables/table-5.csv",
      "narrative": "draft",
      "content": "The table compiles current WHO recommendations on diagnostic approaches relevant to children and adolescents, mainly on rapid molecular tests (Xpert MTB/RIF and Xpert Ultra, Truenat, NAATs, TB-LAMP, LF-LAM and line-probe assays) and on commercial serodiagnostics. Recommendations are grouped by source guideline and topic, each with its strength and certainty of evidence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment of TB disease in children and adolescents",
      "pageStart": 55,
      "pageEnd": 56,
      "target": "../sections/sec-019-5-treatment-of-tb-disease-in-children-and-adoles.md",
      "narrative": null,
      "content": "WHO recommendations that apply to the treatment of TB in children and adolescents (section 5.4). \nThe four new recommendations concern drug-susceptible TB (DS-TB): (i) a four-month regimen for \nchildren and adolescents below 16 years of age with non-severe drug-susceptible TB (section 5.1); \n(ii) a six-month intensive regimen to treat TBM composed of isoniazid, rifampicin, pyrazinamide and \nethionamide (section 5.2); (iii) use of bedaquiline as part of shorter or longer regimens for children \nof all ages to treat MDR/RR-TB (section 5.3.1); and (iv) use of delamanid as part of longer regimens",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the treatment chapter, listing four new recommendations: a four-month regimen for non-severe drug-susceptible TB, a six-month intensive regimen for TB meningitis, and bedaquiline and delamanid for children of all ages with MDR/RR-TB. It notes the source guidelines from which other treatment recommendations are consolidated.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment shortening in children and adolescents with non-severe TB",
      "pageStart": 56,
      "pageEnd": 61,
      "target": "../sections/sec-020-51-treatment-shortening-in-children-and-adolesce.md",
      "narrative": null,
      "content": "adolescents with non-severe TB\nRecommendation:\nIn children and adolescents between 3 months and 16 years of age with non-severe TB (without \nsuspicion or evidence of MDR/RR-TB), a 4-month treatment regimen (2HRZ(E)/2HR) should \nbe used.\n(Strong recommendation, moderate certainty of evidence)\nRemarks\n•\tNon-severe TB is defined as: Peripheral lymph node TB; intrathoracic lymph node TB without \nairway obstruction; uncomplicated TB pleural effusion or paucibacillary, non-cavitary disease, \nconfined to one lobe of the lungs, and without a miliary pattern.\n•\tChildren and adolescents who do not meet",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recommends a four-month regimen for children and adolescents aged 3 months to 16 years with non-severe TB, defining non-severe disease and advising the standard six-month regimen for others. It notes ethambutol should be added in settings with high HIV or isoniazid resistance prevalence. The justification cites potential benefits of shorter treatment for costs, toxicity, drug interactions and adherence. Implementation considerations stress accurate classification of severity and follow-up for up to 12 months after treatment to detect relapse.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment regimens for TB meningitis in children and adolescents",
      "pageStart": 61,
      "pageEnd": 65,
      "target": "../sections/sec-021-52-treatment-regimens-for-tb-meningitis-in-child.md",
      "narrative": null,
      "content": "and adolescents\nRecommendation\nIn children and adolescents with bacteriologically confirmed or clinically diagnosed TB meningitis \n(without suspicion or evidence of MDR/RR-TB), a 6-month intensive regimen (6HRZEto) may be \nused as an alternative option to the 12-month regimen (2HRZE/10HR) \n(Conditional recommendation, very low certainty of the evidence).\nRemarks\n•\tThe shorter intensive regimen is suitable for children and adolescents who have no evidence of \ndrug resistance and in children and adolescents who have a low likelihood of drug-resistant TB, \ne.g. those without risk factors for any",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives a conditional recommendation that a six-month intensive regimen of isoniazid, rifampicin, pyrazinamide and ethionamide may be used as an alternative to the 12-month regimen for TB meningitis in children and adolescents without drug resistance. It notes the 12-month regimen remains an option and that the shorter regimen should not be used in those living with HIV owing to lack of data. Evidence, diagnostic considerations and monitoring of uptake and outcomes are also covered.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Treatment of multi-drug and rifampicin resistant TB in children",
      "pageStart": 65,
      "pageEnd": 77,
      "target": "../sections/sec-022-53-treatment-of-multi-drug-and-rifampicin-resist.md",
      "narrative": null,
      "content": "TB in children \nAround 25 000–32 000 children are estimated to develop MDR/RR-TB every year (75–77). In 2018, \n3398 children (aged below 15 years) were started on second-line treatment for MDR/RR-TB. After \nincreasing to 5586 in 2019, due to the impact of the COVID-19 pandemic, this number dropped back \nto 3234 in 2020, representing only 2.5% of the total number of persons with MDR/RR-TB initiated on \ntreatment and only 10.1%–12.9% of the estimated number of children with incident MDR/RR-TB (78). \nTreatment outcomes reported in a systematic review and individual patient data meta-analysis \ncon",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Addresses treatment of MDR/RR-TB in children, noting an estimated 25 000–32 000 cases a year but only a few thousand started on second-line treatment, with numbers falling during COVID-19. It presents the recommendation on bedaquiline for children of all ages, explaining that earlier advice applied only from age 6 because of limited pharmacokinetic and safety data in younger children. It then covers delamanid for children of all ages within longer regimens. Implementation and monitoring points include the risk of delamanid resistance, cardiac and neuropsychiatric safety monitoring, and recording treatment outcomes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Consolidated recommendations on TB treatment for children and adolescents",
      "pageStart": 77,
      "pageEnd": 81,
      "target": "../sections/sec-023-54-consolidated-recommendations-on-tb-treatment.md",
      "narrative": null,
      "content": "for children and adolescents\nTable 6: WHO recommendations on TB treatment relevant to children and adolescents\nGuidance for national tuberculosis programmes on the management of tuberculosis in \nchildren. Second edition, 2014 (8)\nChildren with pulmonary TB or tuberculous peripheral lymphadenitis who live in settings with \nlow HIV prevalence and/or low prevalence of isoniazid resistance and children who are HIV-\nnegative, can be treated with a three-drug regimen (HRZ) for 2 months followed by a two-drug \n(HR) regimen for 4 months at standard dosages.\n(Strong recommendation, moderate quality of",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reproduces, in Table 6 of WHO's consolidated guidelines on managing tuberculosis in children and adolescents (Module 5), existing WHO recommendations on TB treatment for this age group. These cover regimens for drug-susceptible pulmonary, peripheral lymph node, osteoarticular and meningeal TB, with dosing advice for young infants and the 4-month rifapentine–moxifloxacin regimen from age 12. It also lists recommendations for isoniazid-resistant and multidrug- or rifampicin-resistant TB, ending with notes on treatment monitoring by sputum testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/table-006",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6: WHO recommendations on TB treatment relevant to children and adolescents",
      "pageStart": 77,
      "pageEnd": 80,
      "target": "../tables/table-6.csv",
      "narrative": "draft",
      "content": "The table compiles current WHO recommendations on the treatment of TB relevant to children and adolescents, covering drug-susceptible TB regimens and drug-resistant TB regimens (isoniazid-resistant TB, shorter and longer MDR/RR-TB regimens, BPaL, and monitoring by culture). Recommendations are grouped by source guideline and topic, each with its strength and certainty of evidence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Models of TB care for case detection and provision of TPT in children and adolescents",
      "pageStart": 81,
      "pageEnd": 82,
      "target": "../sections/sec-024-6-models-of-tb-care-for-case-detection-and-provi.md",
      "narrative": null,
      "content": "detection and provision of TPT \nin children and adolescents\nThis chapter contains two new recommendations and other valid WHO recommendations that \napply to patient support and models of care (section 6.2). The two new recommendations, on the \nimplementation of decentralized models of care and integrated family-centred models of care to \nimprove both case detection and the provision of TPT, are described in full detail as this information \nis being published for the first time. Other consolidated recommendations in this chapter are related \nto patient support, health education and counselling,",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the chapter on models of TB care for case detection and preventive treatment in children and adolescents, noting two new recommendations and other consolidated ones on patient support. It describes how paediatric TB capacity is often centralised, primary care staff lack confidence and many chances for contact tracing and prevention are missed, which frames the questions on decentralised and family-centred care.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Decentralized and family-centred, integrated models of care to deliver child and adolescent TB services",
      "pageStart": 82,
      "pageEnd": 87,
      "target": "../sections/sec-025-61-decentralized-and-family-centred-integrated-m.md",
      "narrative": null,
      "content": "models of care to deliver child and adolescent TB \nservices \nRecommendations:\nIn TB high burden settings, decentralized models of care may be used to deliver TB services \nto children and adolescents with signs and symptoms of TB and/or those exposed to TB \n(conditional recommendation, very low certainty evidence).\nFamily-centred, integrated models of care to deliver TB services may be used in children \nand adolescents with signs and symptoms of TB and/or those exposed to TB, in addition to \nstandard models of care (conditional recommendation, very low certainty evidence).\nRemarks\n•\tThese recom",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out two new conditional recommendations, based on very low certainty evidence, that decentralised and family-centred, integrated models of care are options for delivering TB services to children and adolescents with TB symptoms or exposure. Remarks clarify that decentralisation strengthens services at lower levels rather than replacing specialist care, and should target areas with poor access or high prevalence. The section then presents the justification and evidence and implementation considerations, including differentiated service delivery. It ends with monitoring and evaluation advice on planning, registers, sex-disaggregated data and service quality.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Consolidated recommendations on models of TB care relevant to children and adolescents",
      "pageStart": 87,
      "pageEnd": 89,
      "target": "../sections/sec-026-62-consolidated-recommendations-on-models-of-tb.md",
      "narrative": null,
      "content": "care relevant to children and adolescents\nTable 7: WHO recommendations on models of TB care relevant to children and \nadolescents\nWHO consolidated guidelines on tuberculosis. Module 4: treatment – care and support \nduring tuberculosis treatment (100)\nHealth education and counselling on the disease and treatment adherence should be provided \nto patients on TB treatment. \n(Strong recommendation, moderate certainty in the evidence)\nA package of treatment adherence interventions38 may be offered for patients on TB treatment \nin conjunction with the selection of a suitable treatment administration",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Table 7 lists WHO recommendations on care and support during TB treatment that apply to children and adolescents, including health education, adherence interventions such as tracers, material and psychological support, and community- or home-based and video-supported treatment options. Footnotes explain what each type of support involves.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/table-007",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 7: WHO recommendations on models of TB care relevant to children and adolescents",
      "pageStart": 87,
      "pageEnd": 88,
      "target": "../tables/table-7.csv",
      "narrative": "draft",
      "content": "The table compiles current WHO recommendations on models of TB care relevant to children and adolescents, taken from the guidelines on care and support during TB treatment. They cover health education and counselling, treatment adherence interventions, treatment administration options, ambulatory care and decentralized care for MDR-TB, each with its strength and certainty of evidence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Special situations",
      "pageStart": 89,
      "pageEnd": 93,
      "target": "../sections/sec-027-7-special-situations.md",
      "narrative": null,
      "content": "7. Special situations \nThis chapter includes valid WHO recommendations that apply to children and adolescents in \nspecial situations such as for the management of TB in the context of HIV infection or malnutrition \nand optimal feeding of infants of mothers infected with TB. The recommendations have been \nconsolidated from several current WHO guidelines on TB/HIV coinfection and nutrition, namely \nthe WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other \nstakeholders (124), the Consolidated guidelines on HIV prevention, testing, treatment, service delivery",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens the chapter on special situations, covering WHO recommendations for TB in children and adolescents with HIV or malnutrition and feeding of infants of mothers with TB. Table 8 gathers recommendations on HIV testing, co-trimoxazole prophylaxis, antiretroviral therapy eligibility and timing, and TB/HIV care. It also includes nutritional recommendations, such as managing severe acute malnutrition, and ends with a note on pyridoxine with isoniazid.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/table-008",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 8: WHO recommendations on TB/HIV coinfection and nutrition relevant to children and adolescents",
      "pageStart": 89,
      "pageEnd": 92,
      "target": "../tables/table-8.csv",
      "narrative": "draft",
      "content": "The table compiles current WHO recommendations relevant to children and adolescents on TB/HIV coinfection (HIV testing, co-trimoxazole prophylaxis, eligibility for and timing of ART, first- and second-line ART regimens) and on nutrition (severe acute malnutrition, moderate undernutrition and nutrition screening of contacts). Recommendations are grouped by source guideline and topic, each with its strength and certainty of evidence.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Research priorities",
      "pageStart": 93,
      "pageEnd": 97,
      "target": "../sections/sec-028-8-research-priorities.md",
      "narrative": null,
      "content": "8. Research priorities\nThis chapter includes research gaps or priorities that were identified by the GDG members while \nconsidering the evidence related to each of the PICO questions. Addressing the identified research \ngaps has the potential to inform the development of future research questions that can improve \nTB prevention and care. This list of research priorities is not exhaustive; but it complements the \nexisting research agenda outlined in Research priorities for paediatric tuberculosis (127) and other \nWHO guidelines. \nTB screening (adapted from WHO consolidated guidelines on tubercu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists research gaps identified by the guideline development group, grouped by topic such as TB screening, diagnostic approaches and treatment decision algorithms. The priorities call for studies on screening tools for different age groups, validation and implementation of diagnostic algorithms, and research on community perceptions and the quality of TB diagnosis in children.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 97,
      "pageEnd": 105,
      "target": "../sections/sec-029-9-references.md",
      "narrative": null,
      "content": "1.\t Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/\nhandle/10665/346387, accessed 1 December 2021).\n2.\t Marais B. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the \npre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(4):392-402.\n3.\t Martinez L, Cords O, Horsburgh CR, Andrews JR, Pediatric TB Contact Studies Consortium. The risk of \ntuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. \nLancet. 2020;395(10228):973-84.\n4.\t Snow KJ, Sisma",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list for the guideline (127 items), citing mainly WHO TB reports and guidelines and studies on childhood tuberculosis.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 1. WHO recommendations incorporated in the guidelines on the management of TB in children and adolescents",
      "pageStart": 105,
      "pageEnd": 107,
      "target": "../sections/sec-030-annex-1-who-recommendations-incorporated-in-the.md",
      "narrative": null,
      "content": "Annex 1. WHO \nrecommendations incorporated \nin the guidelines on the \nmanagement of TB in children \nand adolescents \nIn order of presentation:\nWHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for \ntuberculosis disease. Geneva: World Health Organization; 2021.\nRecommendations for investigating contacts of persons with infectious tuberculosis in low- and \nmiddle-income countries. Geneva: World Health Organization; 2012.\nWHO guidelines on tuberculosis infection prevention and control, 2019 update. Geneva: World Health \nOrganization; 2019.\nBCG vaccines: WHO p",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 1 lists the WHO guidelines and position papers whose recommendations are incorporated into this module, covering screening, contact investigation, infection control, BCG, preventive treatment, diagnosis, treatment, HIV and nutrition.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 2. Supplementary table",
      "pageStart": 107,
      "pageEnd": 107,
      "target": "../sections/sec-031-annex-2-supplementary-table.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-352522/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Summary of changes to recommendations as included in the second edition of the Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2014",
      "pageStart": 107,
      "pageEnd": 128,
      "target": "../sections/sec-032-summary-of-changes-to-recommendations-as-include.md",
      "narrative": null,
      "content": "included in the second edition of the Guidance \nfor national tuberculosis programmes on the \nmanagement of tuberculosis in children, 2014\n84\nWHO consolidated guidelines on tuberculosis, Module 5: Management of tuberculosis in children and adolescents\nNo.\nRecommendation in Guidance for national \ntuberculosis programmes on the management \nof tuberculosis in children (second edition) 2014, \nand source guideline\nStatus46\nUpdated recommendation and source guideline\n1\n2\nXpert MTB/RIF should be used rather than \nconventional microscopy and culture as the initial \ndiagnostic test in children suspected",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A long annex table comparing each recommendation in WHO's 2014 guidance on managing TB in children with its current status in this module. For each item it gives the original wording and source, whether it was updated, kept, copied to the operational handbook or replaced, and the new wording. Topics include Xpert MTB/RIF and Ultra diagnostic testing, treatment regimens, preventive therapy, HIV and reporting age bands, which change to 0–4, 5–9, 10–14 and 15–19 years. It also lists the new interim recommendation on treatment decision algorithms and ends with WHO Global TB Programme contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
